WO2000077192A1 - Protéine se liant à reg - Google Patents
Protéine se liant à reg Download PDFInfo
- Publication number
- WO2000077192A1 WO2000077192A1 PCT/JP2000/003764 JP0003764W WO0077192A1 WO 2000077192 A1 WO2000077192 A1 WO 2000077192A1 JP 0003764 W JP0003764 W JP 0003764W WO 0077192 A1 WO0077192 A1 WO 0077192A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- reg
- dna
- cells
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to a novel protein that binds to a Reg protein, its gene, and its production and use.
- insulin administration is a symptomatic treatment, and at the same time, it is difficult to maintain physiological blood insulin levels, and when considering the treatment of complications of diabetes such as progression of arteriosclerosis, neuropathy, and eye disease.
- the treatment had limitations.
- Oral diabetic drugs also had side effects such as a decrease in insulin secretion ability, which may be due to excessive load on coronary atherosclerosis ⁇ ⁇ during long-term administration ⁇
- the present inventors have analyzed the mechanism of /? Cell injury and its prevention (H. Yamamoto, et al., Nature 294, 284 (1981); Y. Uchigata, et al., J. Biol Chem. 257). , 6084 (1982); Y. Uchigata, et al., Diabetes 32, 316 (1983); H. Okamoto, Bioessays 2, 15 (1985); H. Okamoto, J. Mol. Med. 77, 74 (1999).
- the present inventors have succeeded in experimentally regenerating and proliferating ⁇ cells (T. Watanabe et al., Proc. Natl. Acad. Sci. USA 91, 3589 (1994); Yonemura, Y. .
- Reg Regeneratinggene
- H. Okamoto J. Mol. Med. 77, 74 (1999)
- K. Terazono et al., J. Biol. Chem. 263, 2111 (1988)
- K. Terazono T. Watanabe, Y. Yonemura, in Molecular biology of the islets of Langerhans, H. Okamoto, Ed. (Cambridge University Press, Cambridge, 1990), pp. 301-313; K. Terazono et al., Diabetologia 33, 250 (1990); T. Watanabe et al., Proc. Natl.
- Reg protein is expected to be applied to the treatment of diabetes as a growth factor of glands / cells that compensates for the weakness of insulin administration, but its large molecular weight makes oral administration difficult. There are many technical issues in clinical application, such as difficulty in getting one. Disclosure of the invention
- An object of the present invention is to provide a novel protein that binds to a Reg protein, a gene thereof, a method for producing them, and a use thereof.
- the protein of the present invention is useful for the development of a new therapeutic agent for diabetes mellitus.
- the present inventors used yeast to examine the effect of Reg protein on cell lines.
- An experiment was performed in which the recombinant Reg protein produced as described above was added to a rat insulinoma cell-derived cell line RINm5F.
- RINm5F rat insulinoma cell-derived cell line
- the addition of Reg protein significantly increased the uptake of 5'-promo-2'-deoxyperidine (BrdU) in RINiii5F cells, and that the growth of the cells was promoted by the Reg protein.
- the present inventors labeled the Reg protein with 125 1 and added it to RINm5F cells to examine its binding activity.
- the present inventors have, to isolate Re g binding protein that functions as a Reg protein receptor, to construct an expression cDNA library with a phage vector from rat ⁇ islet polyA (+) RNA, was used labeled Reg protein
- the gene encoding the Reg binding protein was screened by the West Western method.
- this cDNA was inserted into a mammalian cell expression vector, expressed in C0S-7 cells, and the recombinant Reg protein was added to these cells, the Reg protein could bind specifically to the COS-7 cells. I was assured.
- the present inventors have succeeded in further isolating the cDNA encoding the Reg binding protein by screening a rat Perlangehans islet cDNA library using this cDNA as a probe.
- the cDNA coded for a cell surface protein consisting of 919 amino acids.
- the protein was expressed on the cell surface and the cells bound the Reg protein with high affinity.
- BrdU uptake was induced by the addition of Reg protein, and the cell number increased.
- this Reg-binding protein transmits the signal of the Reg protein and regulates the amount (mass) of the ⁇ cells by controlling the cell proliferation and the like in the ⁇ cells.
- the Reg-binding protein and the gene thereof of the present invention are useful tools for elucidating the etiological mechanism of diabetes, and are also considered to be applicable to the development of therapeutic drugs for diabetes.
- the present invention relates to a Reg protein-binding protein and its gene, and methods for producing and using them, and more specifically,
- MA which encodes a partial peptide of a protein consisting of the amino acid sequence of SEQ ID NO: 2 or 4, (2) a protein or peptide encoded by the DNA according to (1),
- a polynucleotide that hybridizes with a DNA consisting of the nucleotide sequence of SEQ ID NO: 1 or 3 or a complementary DNA thereof and has a chain length of at least 15 bases
- (11) A method for screening a compound that promotes or inhibits signal transduction caused by the activation of the protein according to (2), (a) contacting a Reg protein with cells expressing the protein of (2) on the surface thereof in the presence of a test sample;
- the (14) selected from the group consisting of a Reg binding agent, a regulator of intracellular signal transduction in response to a Reg protein, a cell growth regulator, a DNA synthesis regulator, and an apoptosis regulator.
- a Reg binding agent selected from the group consisting of a Reg binding agent, a regulator of intracellular signal transduction in response to a Reg protein, a cell growth regulator, a DNA synthesis regulator, and an apoptosis regulator.
- the present invention relates to a novel protein (Reg binding protein) that is expressed in the kidney and binds to a Reg protein.
- the nucleotide sequences of the isolated rat “Reg-binding protein” cDNA included in the present invention are shown in SEQ ID NOs: 1 and 3, and the amino acid sequences of the “Reg-binding protein” encoded by these cDNAs are shown in SEQ ID NO: Shown in 2 and 4.
- One of the cDNAs encoding the rat Reg binding protein of the present invention contains an open reading frame encoding a protein of 364 amino acid residues (SEQ ID NO: 2) (SEQ ID NO: 1). Screening using this cDNA as a probe also isolates a cDNA (SEQ ID NO: 3) encoding a rat Reg binding protein containing an open reading frame encoding a 919 amino acid residue protein (SEQ ID NO: 4). Was completed.
- the rat “Reg binding protein” of the present invention is expressed on the cell surface, Has the activity of binding to As mentioned above, the Reg protein is a regenerative growth factor that is specifically expressed during the renewal of cells, and its proteins and genes have been shown to have therapeutic potential for diabetes.
- the Reg binding protein of the present invention functions as a receptor for this Reg protein, and is considered to be involved in the regulation of the physiological functions of cells, including the control of proliferation of ⁇ cells. Therefore, the use of the Reg-binding protein of the present invention as a research target to elucidate the mechanism of the pathogenesis of diabetes and as a tool for the development of therapeutic agents for diseases involving the function of ru ⁇ cells (such as diabetes) are considered.
- the type I Reg protein including the rat and human Reg proteins used in this example is expressed in regenerated islets (H. Okamoto, J. Mol. Med. 77, 74 (1999); K. Terazono, et al. al., J. Biol. Chem. 263, 2111 (1988); K. Terazono, T. Watanabe, Y. Yonemura, in Molecular biology of the islets of Langerhans, H. Okamoto, Ed. (Cambridge University Press, Cambridge, 1990), pp. 301-313; K. Terazono et al., Diabetologia 33 , 250 (1990); H. Okamoto, J. Hepatobiliary Pancreat. Surg. 6, 254 (1999)).
- the identified Reg receptor is likely to function as a receptor for the product of the Reg family gene in various tissues and cells under physiological and pathological conditions.
- the protein of the present invention can be used in addition to diabetes and gastrointestinal swelling (Asahara, M. et al., Gastroenterology 111, 45-55 (1996); Fukui, H. et al., Gastroenterology 115, 1483-1493 (1998)), neurodegenerative disease (Livesy, FJ et al., Nature 390, 614-618 (1997)), and prostatitis (Christa, L. et al., Am. J. Phsiol. 271, G993-G1002 (1996); Ortiz, E. et al., Gastroenterology 114, 808-816 (1998)).
- Reg protein-Reg binding protein when abnormalities of Reg protein-Reg binding protein (eg, overstimulation) occur in tumors, etc., administration of soluble Reg-binding protein can suppress overstimulation and suppress tumor growth, etc. It is also conceivable to apply the Reg binding protein itself to therapy.
- a protein structurally similar to rat “Reg binding protein” is also included as long as it has an activity of binding to the Reg protein.
- Such structurally similar proteins include mutants of “Reg-binding protein” and “Reg-binding proteins” derived from other organisms.
- Such proteins can be prepared by those skilled in the art, for example, using a known mutagenesis method.
- Methods for modifying amino acids in proteins known to those skilled in the art include, for example, the Kunkel method (Kunkel, TA (1985) Proc. Natl. Acad. Sci. USA 82, 488), Oligonucleotide-directed Dual Amber (ODA). (Hashimoto-Gotoh, T. et al. (1995) Gene 152, 271-275), PCR-restriction enzyme method (Ito, W. et al. (1991) Gene 102, 67-70), ODA-PCR method (Hashimoto-Gotoh, T. et al. (1995) Gene 152, 271-275; Ito, W.
- the number of amino acid modifications in the protein is not limited, but is usually within 50 amino acids, preferably within 10 amino acids, more preferably within 5 amino acids if artificially performed. Amino acid mutations in proteins can also occur naturally. Proteins that differ in amino acid sequence from the native rat “Reg-binding protein” due to artificial or natural amino acid substitutions, deletions, additions, and / or insertions as long as they have the activity to bind to the Reg protein. Are also included in the present invention.
- the amino acid to be substituted is preferably an amino acid having properties similar to the amino acid before substitution.
- Ala, Val, Leu, Ile, Pro, Met, Phe, and Trp are all classified as non-polar amino acids, and are considered to have similar properties to each other.
- examples of the non-charger include Gly ⁇ Ser ⁇ Thr ⁇ Cys and Tyr ⁇ Asn ⁇ Gin.
- acidic amino acids include Asp and Glu.
- basic amino acids include Lys, Arg, and His.
- the protein in which the amino acid of the rat “Reg binding protein” is deleted includes a protein having only an extracellular region.
- proteins in which amino acids have been added to rat “Reg-binding protein” include rat “Reg-binding protein” and other peptides. Fusion proteins are included.
- the preparation of a protein that is structurally similar to rat “Reg-binding protein”, which has the activity to bind to the Reg protein can be performed by a known hybridization technique (edited by Sambrook et al., Molecular Cloning, 2nd Edition, Cold Spring). 'Harba-Laboratory 1, 1989 (Sambrook, J. et al. (1989) Molecular Cloning 2nd ed., Cold Spring Harbor Laboratory Press)) and polymerase chain reaction technology (edited by Sambrook et al., Molecular' cloning ' Second edition, Cold'Spring-Harber-Lab., 1989 (Sambrook, J. et al.
- rat “Reg-binding protein” cDNA sequence SEQ ID NO: 1 or 3
- an oligonucleotide that specifically hybridizes to rat “Reg-binding protein” cDNA is used.
- As a primer it is common to isolate DNA highly homologous to rat “Reg-binding protein” from various other organisms and obtain a protein structurally similar to rat “Reg-binding protein” from the isolated DNA. It is a means.
- a protein encoded by a DNA hybridizing with a rat “Reg binding protein” cDNA is included as long as it has an activity of binding to the Reg protein.
- Other organisms from which such proteins can be isolated include, but are not limited to, humans, monkeys, mice, rabbits, goats, rabbits, bushes, dogs, and the like. In order to isolate a DNA encoding such a protein, for example, it is considered that Perangerhans islet cells of these organisms are suitable as a material.
- DNA encoding a "Reg binding protein" derived from an organism other than a rat usually has a high homology to the nucleotide sequence of the rat "Reg binding protein” cDNA (SEQ ID NO: 1 or 3).
- High homology means at least 60% or more, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, most preferably at the nucleotide sequence level. Indicates 99% or more sequence identity.
- FASTA search for sequences that maintain similarity in a long range
- BLAST search for sequences with high local similarity
- SSEARCH search using the Smith-Waterman algorithm
- rat "Reg-binding protein" cDNA can be used to isolate a cDNA encoding a protein functionally equivalent to the rat "Reg-binding protein” from another organism.
- 6 x SSC I 5 x FBP I 0.5% SDS / 0.2 mg / ml salmon (herring) sperm DNA / 10% formamide solution hybridized at 42 ° C (low stringency conditions) It can be performed.
- 6X SSC I 5X FBP / 0.5% SDS / 0.2mg / ml salmon (herring) sperm DNA / 30% formamide solution hybridized at 42 ° C (intermediate stringent conditions) Perform a trial.
- hybridization is carried out with a solution of 6 ⁇ SSC I 5 ⁇ FBP I 0.5% SDS / 0.2 mg / ral salmon (herring) sperm DNA / 50% formamide at 50 ° C. (high stringent conditions).
- factors that influence the stringency of the hybridization may be a number of factors, such as temperature, formamide concentration, and salt concentration. It is possible to achieve stringency.
- the protein of the present invention can be prepared as a recombinant protein using a gene recombination technique, in addition to a natural protein.
- the natural protein is obtained, for example, by using an antibody against a “Reg-binding protein” described below to an extract of a tissue (eg, a islet of Langerhans /? Cells) in which “Reg-binding protein” is considered to be expressed. It can be prepared by a method using two-tipped mouth chromatography.
- a recombinant protein can be prepared by culturing cells transformed with a DNA encoding a “Reg-binding protein” as described below, and expressing and recovering this protein.
- the present invention includes a partial peptide of the protein of the present invention.
- the peptide include, among the proteins of the present invention, a peptide corresponding to the binding site to the Reg protein.
- the partial peptide of the protein of the present invention can be used as an agonist of the protein of the present invention, an antagonist of the Reg protein, and the like by being administered to a living body. These partial peptides are useful as activators and inhibitors of signal transmission via the protein of the present invention.
- Examples of the partial peptide of the present invention include a partial peptide at the N-terminal region and a partial peptide at the C-terminal region of the protein of the present invention. These peptides are used for preparing antibodies. be able to .
- the partial polypeptide having an amino acid sequence specific to the protein of the present invention has a chain length of at least 7 amino acids, preferably at least 8 amino acids, and more preferably at least 9 amino acids.
- the partial peptide of the present invention can be produced, for example, by a genetic engineering technique, a known peptide synthesis method, or by cleaving the protein of the present invention with an appropriate peptidase.
- partial peptides containing a region that binds to the Reg protein can be used to bind the Reg protein.
- Such partial peptides can be used as Reg protein binders.
- the present invention also relates to a DNA encoding the protein of the present invention.
- the MA encoding the protein of the present invention is not particularly limited as long as it can encode these proteins, and includes cDNA, genomic DNA, and synthetic DNA.
- a DNA having an arbitrary nucleotide sequence based on the degeneracy of the genetic code is included.
- CDNA encoding the protein of the present invention for example, SEQ ID NO: cDNA or fragment thereof according to 1 or 3, their complementary RNA, or synthetic oligonucleotides comprising a portion of sequence of the cDNA 32 P etc.
- Screening can be carried out by labeling with cDNA and hybridizing to a cDNA library derived from a tissue (eg, a kidney) expressing the protein of the present invention.
- tissue eg, a kidney
- oligonucleotides corresponding to the nucleotide sequences of these cDNAs can be synthesized, and cDNA derived from an appropriate tissue (for example, a kidney) can be amplified and cloned into a type by polymerase chain reaction.
- Genomic DNA includes, for example, the cDNA of SEQ ID NO: 1 or 3 or a fragment thereof
- Screening can be performed by labeling a complementary RNA or a synthetic oligonucleotide containing a part of the sequence of the cDNA with 32 P or the like, and hybridizing the labeled oligonucleotide to a genomic DNA library.
- oligonucleotides corresponding to the nucleotide sequences of these cDNAs can be synthesized, and genomic DNA can be amplified to form type II by polymerase chain reaction and then cloned.
- a synthetic DNA can be prepared, for example, by chemically synthesizing an oligonucleotide having a partial sequence of the cDNA shown in SEQ ID NO: 1 or 3, annealing it to make it double-stranded, and binding it with DNA ligase. .
- These DNAs are useful for producing recombinant proteins. That is, a DNA obtained by inserting a DNA encoding the protein of the present invention (for example, the DNA of SEQ ID NO: 1 or 3) into an appropriate expression vector and introducing the vector into an appropriate cell. By culturing the transformant and collecting the expressed protein, the protein of the present invention can be prepared as a recombinant protein.
- the protein of the present invention can be prepared as a purified or partially purified protein, or expressed in a mammalian cell, and prepared as a membrane-bound form.
- Specific host-vector systems include, for example, the E. coli-pGEX system (Amersham Armasiasia Biotech; expressed as a fusion protein with GST), the E. coli-pHB6 system and the pVB6 system (Roche Diagnostics). Stick; expressed as a fusion protein with 6 histidines), E. coli-pMAL system (New England Biolabs; expressed as a fusion protein with maltose binding protein), E.
- coli-pTYB system New England Biolabs; expressed as a fusion protein with Intein, then the Interin portion is cleaved in the presence of DTT, making it easy to purify only the target protein
- Pichia-pPIC and pGAP Invitorogen
- mammalian cells eg COS -7) — pCI-neo system (Promega), pHook system (Invitorogen), etc.
- the method of introducing a vector into a host is known as transformation or electroporation into known E. coli cells.
- transformation into electrocompetent cells prepared by Pichia Easy Comp Kit see Example 1
- electroporation electroporation into mammalian cells or known cationic It can be performed by a lipofection method using a lipid or the like.
- the recombinant protein expressed in the host cell can be purified by a known method.
- the protein of the present invention is expressed in the form of a fusion protein in which a tag of a histidine residue or glutathione S-transferase (GST) is bound at the N-terminus, for example, a nickel column or glutathione is used, respectively. It can be purified using a thiophene sepharose column or the like.
- the DNA encoding the protein of the present invention can also be applied to gene therapy for diseases caused by the mutation.
- gene therapy using a virus vector such as vaccinia virus or retrovirus can be considered.
- the “Reg-binding protein” is introduced into a transplantation tract or a islet of Langerhans using these recombinant viruses under culture conditions, and transplantation is performed to expand Teng cells.
- the transplantation treatment effect can be improved and the organ for transplantation can be effectively used.
- the present invention also relates to a polynucleotide that hybridizes with a DNA consisting of the nucleotide sequence of SEQ ID NO: 1 or 3 or a complementary DNA thereof and has a chain length of at least 15 bases.
- the polynucleotide is preferably a polynucleotide that specifically hybridizes with DNA consisting of the nucleotide sequence of SEQ ID NO: 1 or 3, and has a chain length of at least 15 bases.
- “Specifically hybridize” means under ordinary hybridization conditions, preferably under the above-mentioned intermediate stringent hybridization conditions, and more preferably under the above-mentioned highly stringent hybridization conditions. Means that cross-hybridization with DNA encoding other proteins does not significantly occur.
- hybridization may be performed under the above conditions.
- polynucleotides include probes or primers, nucleotides or nucleotide derivatives (eg, antisense oligonucleotides and ribozymes) capable of specifically hybridizing to DNA encoding the protein of the present invention or DNA complementary to the DNA. Etc.) are included.
- the peptide can be used for cloning of a gene or cDNA encoding the protein of the present invention, or for amplification by PCR. Further, it is useful for detection and quantification of RNA encoding the protein of the present invention. Furthermore, methods such as restriction fragment length polymorphism (RFLP) and single-stranded DNA conformational polymorphism (SSCP) can be used to detect gene or cDNA mutations, polymorphisms, or abnormalities (such as genetic diagnosis).
- RFLP restriction fragment length polymorphism
- SSCP single-stranded DNA conformational polymorphism
- the polynucleotide of the present invention can be used for the examination of the kidney, for example, Can be used for inspection. Further, the polynucleotide of the present invention can also be used for testing for diabetes. For example, it is possible to isolate a renal tissue sample from a subject and examine the expression level of the protein of the present invention in this tissue for abnormalities using Northern hybridization, RT-PCR, or a DNA chip (DNA microarray). it can.
- DNA or RNA encoding the protein of the present invention can be determined by sequence determination or by SSCP or RFLP.
- the polynucleotide when used as a test reagent, it can be appropriately mixed with sterile water, a buffer, a salt, or the like.
- the protein of the present invention or a partial peptide thereof, a DNA encoding the protein or the peptide, and a vector into which the DNA is inserted may be a compound that inhibits the binding between the protein of the present invention and a Reg protein described below. It can be used for screening, and for screening compounds that promote or inhibit signal transduction (eg, cell proliferation activity or cell DNA synthesis activity) resulting from activation of the protein of the present invention. These screenings can also be applied to the treatment or prophylaxis of diseases caused by abnormalities in the amount or function of cells, including diabetes. In addition to diabetes, it can be used for the treatment or prophylaxis of therapeutic or prophylactic agents for gastrointestinal tumors, neurodegenerative diseases, inflammatory diseases, tumors and the like.
- the present invention also relates to an antibody that binds to the protein of the present invention.
- the antibodies of the present invention include polyclonal antibodies and monoclonal antibodies.
- Polyclonal antibody For example, “Reg-binding protein” prepared from biological materials (eg, kidney islets of Langerhans), recombinant “Reg-binding protein” produced by the host-vector system described above, or general peptide synthesis A method known in the art using a partial peptide synthesized by the method as an antigen
- Monoclonal antibodies were prepared from biomaterials (eg, liver islets of Langerhans)
- polyclonal antibodies For polyclonal antibodies, serum, and for monoclonal antibodies, common biochemicals such as ammonium sulfate fraction, protein G Sepharose column, antigen-fixed affinity column, etc. from aseptic fluid of hybridoma culture supernatant or ascites of animals inoculated with hybridoma.
- the antibody is purified by the technique.
- the antibody thus prepared is used for affinity purification of the protein of the present invention.
- examination and diagnosis of diseases caused by abnormal expression or structural abnormality of the protein of the present invention, and protein of the present invention It can be used for detection of the expression level of.
- the antibody of the present invention can also be used for the examination of the kidney, for example, the examination of human cells. Further, the antibody of the present invention can also be used for testing for diabetes.
- a liver tissue sample can be isolated from a subject, and the expression level or structure of the protein of the present invention in this tissue can be examined for abnormalities by Western plot, immunohistochemistry, ELISA, EIA and the like.
- test reagents combine sterile water, buffers, salts, stabilizers, preservatives, etc. as appropriate. Can be matched. It is also conceivable to use the antibodies of the present invention for antibody therapy.
- the antibody of the present invention is used for antibody therapy, it is preferably a humanized antibody or a human antibody.
- human lymphocytes are fused with HGPRT (hypoxantine-guanine phosphoribosyl transferase) -deficient mouse myeloma, and human-mouse heterohybridoma is selected in HAT medium.
- HGPRT hyperxantine-guanine phosphoribosyl transferase
- human-mouse heterohybridoma is selected in HAT medium.
- the myeloma cells are selected by a known RIA or ELISA method using “Reg-binding protein” as an antigen to obtain a clone that produces a humanized monoclonal antibody against “Reg-binding protein”. Purification of the antibody can be performed as described above.
- the present invention also relates to a method for screening a compound that binds to the protein of the present invention.
- Such screening includes (a) a step of bringing a test sample into contact with the protein of the present invention or a partial peptide thereof, and (b) detecting the binding between the protein of the present invention or a partial peptide thereof and the test sample. And (c) selecting a compound that binds to the protein of the present invention or a partial peptide thereof.
- the protein of the present invention can be used for screening as a purified protein, in a form expressed on the cell surface, or as a cell membrane fraction, depending on the screening technique.
- test sample examples include, but are not limited to, a cell extract, an expression product of a gene library, a synthetic low-molecular compound, a synthetic peptide, and a natural compound.
- the test sample is used after being appropriately labeled as necessary.
- label examples include, but are not limited to, radioactive labels and fluorescent labels.
- Screening for a protein that binds to the protein of the present invention includes, for example, a culture supernatant of a cell that is expected to express the protein that binds to the protein of the present invention on an affinity column on which the protein of the present invention is immobilized.
- a protein that binds to the protein of the present invention can be obtained by applying a cell extract and purifying a protein that specifically binds to the column. Can be screened.
- a cDNA library using a phage vector is prepared from a tissue or a cell (for example, a cell) that is expected to express a protein that binds to the protein of the present invention, and this is prepared on agarose. After immobilizing the protein on the filter and expressing it, the labeled protein of the present invention is reacted to detect the break that expresses the protein to be bound.
- the method can be carried out according to a “two hybrid system” or the like for detecting the binding between the protein of the present invention and the test protein.
- a method of screening a molecule to be bound by allowing a synthetic compound, a natural product bank, or a random phage peptide display library to act on the immobilized protein of the present invention and a high-throughput method using combinatorial chemistry technology.
- a method for isolating a compound that binds to the protein of the present invention by screening using a put is also a technique well known to those skilled in the art.
- the present invention also relates to a method for screening a compound that inhibits the binding between the protein of the present invention and a Reg protein.
- Screening includes: (a) a step of bringing the protein of the present invention into contact with a Reg protein in the presence of a test sample; (b) a step of detecting the binding between the protein of the present invention and the Reg protein; (c) Selecting a compound that reduces the binding.
- the protein of the present invention can be used for screening as a purified protein, in a form expressed on the cell surface, or as a cell membrane fraction.
- Reg protein is usually Used for screening as a purified protein.
- As the Reg protein for example, human REG I or rat Reg I can be used. These proteins may be prepared as recombinant proteins (see Example 1). Reg protein may be labeled with a radioisotope such as [ 1251 ] if necessary.
- test sample examples include, but are not limited to, a cell extract, an expression product of a gene library, a synthetic low-molecular compound, a synthetic peptide, and a natural compound.
- the screening can be performed, for example, as follows.
- a cell expressing the protein of the present invention, or a membrane fraction prepared therefrom, is contacted with a labeled ligand (Reg protein) in the presence of a test sample to form a labeled ligand that binds to the protein of the present invention.
- a labeled ligand (Reg protein)
- a test sample to form a labeled ligand that binds to the protein of the present invention.
- Measure the amount Select a compound that reduces the amount of this ligand as compared to when no test sample is present.
- the binding between the protein of the present invention and the Reg protein can also be measured using the above-described BIACORE or microphysiome.
- the compound thus isolated is a candidate for the agonist of the protein of the present invention.
- the present invention also relates to a method for screening for a compound that promotes or inhibits signal transduction caused by activation of the protein of the present invention.
- screening includes: (a) a step of contacting a Reg protein with a cell expressing the protein of the present invention on the surface in the presence of a test sample; and (b) a change of the cell in response to the Reg protein stimulation. And (c) selecting a compound that enhances or suppresses the change in the cells as compared with the case of detection in the absence of the test sample (control). It is possible.
- Cells expressing the protein of the present invention on its surface are prepared by inserting the DNA encoding the protein of the present invention into an appropriate expression vector and introducing the vector constructed thereby into an appropriate host cell.
- the host cell include cells such as RINm5F cell, CH0 cell, and COS-7 cell.
- PCI-neo as vector (Promega), pHook (Invitrogen) and the like.
- test sample examples include, but are not limited to, a cell extract, an expression product of a gene library, a synthetic low-molecular compound, a synthetic peptide, and a natural compound. Further, a compound isolated by the above-described screening using the binding to the protein of the present invention as an index can be used as a test sample.
- Reg protein is usually used for screening as a purified protein.
- As the Reg protein for example, human REG I or rat Reg I can be used. These proteins may be prepared as recombinant proteins (see Example 1).
- Changes in cells in response to Reg protein stimulation include, for example, changes in cell growth activity, changes in cell DNA synthesis activity, changes in the degree of cell apoptosis, and phosphorylation of the protein of the present invention or a protein that transmits its signal. Examples include, but are not limited to, oxidation and changes in the expression of specific genes in cells.
- Cellular DNA synthesis can be detected, for example, by measuring the incorporation of 5'-bromo-2'-dexperidine (BrdU) as shown in the Examples. Alternatively, it may be performed by adding 3 ⁇ 4-thymidine to cells and measuring the radioactivity incorporated into the cells. ⁇ ⁇ ⁇ ⁇ -thymidine incorporation into cells is commonly used to measure the effect of promoting or inhibiting DNA synthesis. This method has advantages such as handling a relatively large amount of sample and high sensitivity. For screening of compounds that promote or inhibit DNA synthesis, specifically, for example, seed cells on a multi-well plate or the like and incubate for about 1 to 2 days, change to the medium containing the test sample, and change to 24 hours, etc.
- RhdU 5'-bromo-2'-dexperidine
- cell proliferation can be performed by measuring the number of cells or the number of colonies, or by adding a dye such as MTT or Alamar Blue to the cells and measuring the color development depending on the number of cells.
- the MTT method measures cell proliferation activity by color development with MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide). It acts on the mitochondrial respiratory chain to produce MTT formazan. This production reflects the number of cells. Specifically, for example, the cells are cultured in a 96-well plate, and the test sample is allowed to act. Then, 10-5 of a 5 mg / ml MTT solution is added, and the mixture is incubated for 4 hours.
- Cell apoptosis can be measured using, for example, changes in nuclear morphology (condensation and fragmentation of nuclei) and chromosome fragmentation (dala formation). Specifically, apoptosis can be detected by, for example, the TUNEL method [Y. Gavriel et al., J. Cell Biol. 119, 493 (1992)] (see Example 11).
- Protein phosphorylation is thought to occur at serine, threonine, or tyrosine residues. These changes in phosphorylation can be detected by measuring the phosphorylation state of intracellular proteins by the Wessin method ⁇ immunoprecipitation with anti-phosphorylated serine, threonine, or tyrosine antibodies. Proteins to be phosphorylated are expected to be MAP kinase system-STAT system or Fos-Jun protein involved in cell growth, but are not limited to these exemplified proteins.
- the change in the expression of a specific gene can be detected by using a repo overnight gene. That is, the measurement can be performed by connecting the repo overnight gene downstream of the promoter of the gene and detecting the expression of the repo overnight gene. Changes in the expression of specific genes can be detected by methods such as Northern blotting or RT-PCR, such as methods for detecting mA, methods for detecting proteins that are translation products of genes using antibodies, and gene translation. It can also be measured by a method for detecting the activity of the product protein.
- Compounds isolated by these screenings include, for example, 1) a compound that binds to the protein of the present invention and promotes or inhibits its activity, and 2) a ligand of the protein of the present invention such as the protein of the present invention or the Reg protein.
- a compound that binds and promotes or inhibits the binding of the protein of the present invention to the ligand 3 a compound that binds to the ligand of the protein of the present invention and promotes or inhibits its activation; 4 a change in the cell from the protein of the present invention
- These compounds can be applied to preventive and therapeutic agents for diseases caused by abnormalities in the signal transduction system mediated by the protein of the present invention (for example, diseases caused by abnormalities in cancer cells). For example, it may be applied to the treatment of diabetes.
- the DNA of the present invention, the protein of the present invention or the partial peptide thereof, the vector containing the DNA of the present invention, the antibody against the protein of the present invention or the partial peptide thereof, and the compound which can be isolated by the above screening are used alone or It can be used as a drug in combination with other compounds.
- the agents of the present invention include reagents and medicaments.
- the protein of the present invention since the protein of the present invention has an activity of binding to the Reg protein, the protein of the present invention and its partial peptide can be used to bind to the Reg protein. Such a protein or peptide can be used for detection of a Reg protein, affinity purification, and the like.
- the protein of the present invention or its partial peptide By bringing the protein of the present invention or its partial peptide into contact with the Reg protein, the protein of the present invention or its partial peptide can be bound to the Reg protein.
- the protein of the present invention or its partial peptide has not been purified. Or expressed on the cell membrane surface. Also, it may be bound to a carrier.
- a carrier There is no limitation on the origin of the Reg protein to be bound, and Reg proteins from mice, rats, humans and the like can be bound.
- a DNA encoding the protein of the present invention or a partial peptide thereof and a vector into which the DNA is inserted are used for the same purpose by expressing the protein of the present invention or the partial peptide thereof in cells. be able to.
- the drug containing the protein of the present invention and its partial peptide, the DNA encoding them, or the vector into which the DNA is inserted can be used as a Reg protein binding agent.
- the protein of the present invention functions as a receptor for Reg protein. Therefore, the protein of the present invention can be used to regulate (promote or suppress) intracellular signal transduction in response to the Reg protein. By activating the protein of the present invention, signal transmission is promoted, and conversely, by inhibiting the activation of the protein of the present invention, signal transmission is blocked.
- the protein of the present invention eg, SEQ ID NO: 4
- a ligand or agonist of the protein of the present invention such as a Reg protein to activate the protein of the present invention, and a signal is produced in the cell.
- the cells are preferably cells of a cell line or epithelial cells.
- a protein that binds to a Reg protein but does not transmit a signal into a cell can be used to block signaling of the Reg protein.
- proteins include proteins that retain the binding region to the Reg protein but do not have a downstream signaling site. By expressing such a protein in a cell or by adding it extracellularly, signal transmission by the Reg protein can be blocked.
- DNA encoding the protein of the present invention or a partial peptide thereof and a vector into which the DNA is inserted may be used for the same purpose by expressing the protein of the present invention or a partial peptide thereof in cells. Can be.
- an antibody that binds to the protein of the present invention or a partial peptide thereof, and a compound that can be isolated by the screening of the present invention can be used for the same purpose.
- the protein of the present invention or its The partial peptide, the DNA encoding the protein or the peptide, the vector into which the DNA is inserted, the antibody of the present invention, and the compound that can be isolated by the screening of the present invention are capable of signaling intracellular signaling in response to the Reg protein.
- Modulators such as accelerators or inhibitors
- intracellular signal transduction in response to the Reg protein includes promotion of cell DNA synthesis and regulation (promotion or suppression) of cell growth. That is, it indicates that the protein of the present invention can be used to promote DNA synthesis of cells and to promote or suppress cell proliferation.
- the target cell is preferably a cell of a cell line or an epithelial cell.
- a vector that expresses the protein of the present invention eg, SEQ ID NO: 4
- proteins that bind to the Reg protein but do not transmit signals into cells can be used to suppress DNA synthesis or suppress cell growth.
- proteins include proteins that retain the binding region to the Reg protein but do not have a downstream signaling site.
- a DNA encoding the protein of the present invention or a partial peptide thereof and a vector into which the DNA has been inserted can also be used for the same purpose as described above by expressing the protein of the present invention or a partial peptide thereof in cells.
- an antibody that binds to the protein of the present invention or a partial peptide thereof, and a compound that can be isolated by the screening of the present invention can also be used for regulating DNA synthesis or cell growth.
- an antibody or compound acting as a ligand or agonist of the protein of the present invention can promote the proliferation of cells (eg, 5 cells) by administering it to a living body. Administration can be performed in vitro and in vivo.
- Agents eg, accelerators or inhibitors.
- signal transduction caused by activation of the protein of the present invention includes induction of cellular apoptosis. That is, the protein of the present invention can be used for regulating cell apoptosis (inducing or suppressing apoptosis).
- DNA encoding the protein of the present invention or a partial peptide thereof and a vector into which the DNA is inserted can be used for the same purpose by expressing the protein of the present invention or a partial peptide thereof in cells. .
- an antibody that binds to the protein of the present invention or a partial peptide thereof, and a compound that can be isolated by the screening of the present invention can also be used for regulating apoptosis.
- the target cell is preferably a cell of a cell line or an epithelial cell.
- Apoptosis can be induced by contacting a cell that expresses the protein of the present invention with a ligand of the protein of the present invention (eg, a Reg protein) at a high concentration.
- the Reg protein is contacted with the cells, for example, at a concentration higher than ⁇ , preferably at a concentration of 500 nM or more, more preferably at a concentration of ⁇ or more.
- a vector expressing the protein of the present invention eg, SEQ ID NO: 4
- a protein that binds to the Reg protein but does not transmit a signal into cells can be used to suppress the induction of apoptosis by the Reg protein.
- Apoptosis can be suppressed by expressing such a protein in cells or by adding it extracellularly.
- the protein of the present invention or a partial peptide thereof, DNA encoding the protein or peptide, a vector into which the DNA is inserted, the antibody of the present invention, and the compound that can be isolated by the screening of the present invention include cell apoptosis.
- the protein of the present invention or a partial peptide thereof, a DNA encoding the protein or the peptide, a vector into which the DNA has been inserted, an antibody of the present invention, and a compound which can be isolated by the screening of the present invention include: According to a known pharmaceutical technique, a composition can be obtained by combining distilled water, a buffer, a salt, BSA, glycerol, a stabilizer, a preservative, a surfactant and the like. Further, the drug of the present invention can be used as a reagent for examining a kidney as described above. It is also useful as a pharmaceutical composition for treating or preventing diabetes, gastrointestinal tract tumors, neurodegenerative diseases, phlegmitis, tumors and the like.
- the agent of the present invention When the agent of the present invention is used as a medicament, the protein of the present invention or a partial peptide thereof, a DNA encoding the protein or peptide, a vector into which the DNA has been inserted, an antibody of the present invention, and a DNA of the present invention
- a suitable combination with a pharmacologically acceptable carrier or medium specifically, sterile water, physiological saline, dextrose, glycerol, ethanol, vegetable oil, emulsifier, suspending agent, surfactant, stabilizer, etc. May be formulated and administered.
- the pharmaceutical composition of the present invention may be in the form of an aqueous solution, tablet, capsule, troche, balical tablet, elixir, suspension, capsule, or the like.
- the content of the active compound may be appropriately determined.
- Administration to a patient can be performed, for example, by intraarterial injection, intravenous injection, subcutaneous injection, etc., or intranasally, transbronchially, intramuscularly, or orally by a method known to those skilled in the art. Administration can be systemic or local.
- the dose varies depending on the weight and age of the patient, the administration method, the symptoms, and the like, and those skilled in the art can appropriately select an appropriate dose.
- Administration can be carried out once to several times.
- the DNA may be incorporated into a vector for gene therapy to perform gene therapy.
- Administration can be performed ex vivo or in vivo.
- the dose and the administration method vary depending on the patient's body weight, age, symptoms and the like, but can be appropriately selected by those skilled in the art.
- FIG. 1 shows the results of measuring the uptake of BrdU when human REG protein (REGIa) was added to RINm5F cells derived from rat insulinoma (Example 3 and FIG. 2 show RINm5F cells).
- 5 shows the results of measuring the binding to cells when [ 125 1] -labeled rat Reg protein (Reg I) was added to the cells (Example 4). Only “Hot + 100xCold” indicates the results when both labeled rat Reg protein and 100 times the amount of unlabeled rat Reg protein were added.
- Figure 3 shows the results of expressing the isolated Reg-binding protein in COS-7 cells and measuring the binding to cells when [ 125 1] -labeled rat Reg protein (Reg I) was added.
- PCI-neo indicates an empty vector
- pCI-167.1 indicates the results of cells into which the Reg-binding protein expression vector has been introduced.
- (-) shows the result when only labeled rat Reg protein was added
- (+) shows the result when both labeled rat Reg protein and 100-fold amount of unlabeled rat Reg protein were added.
- Figure 4 shows rat Reg binding protein (Reg receptor) (rEXTL3) (SEQ ID NO: 4), human EXTL3 / EXTR1 (hEXTL3) (GenBank accession numbers AF001690 and AB007042) (SEQ ID NO: 5), human EXT2 (hEXT2) (GenBank accession number U64511) (SEQ ID NO: 6), human EXT1 (hEXTl) (GenBank accession number S79639) (SEQ ID NO: 7), human EXTL1 (hEXTLl) (GenBank accession number) U67191) (SEQ ID NO: 8) and the predicted protein amino acid sequence of human EXTL2 (hEXTL2) (GenBank accession number AF000416) (SEQ ID NO: 9) are aligned (Example 7).
- the transmembrane domain is underlined.
- the numbers in the right column correspond to amino acid residues.
- Residues identical to rat Reg binding protein (rEXTL3) are shown in dots.
- a hyphen indicates that there is no residue corresponding to rat Reg binding protein (rEXTL3).
- FIG. 5 is a diagram showing the cell distribution of the Reg binding protein.
- Lane 1 control Homogenates of COS-7 cells transfected with vector;
- Lanes 2-6 homogenates of C0S-7 cells transfected with Reg-binding protein expression vector, membrane fraction, mitochondrial fraction, microsome fraction, and cytochrome Tosol fraction (Example 8).
- 10 / g of the protein was electrophoresed, and a Western plot was performed using an antibody against the HA fragment added to the Reg-binding protein. It can be seen that the Reg protein is expressed on the cell surface.
- FIG. 6 shows that the rat homologue of human EXTL3 / EXTR1 is a cell surface type Reg binding protein (Example 9).
- FIG. 3 shows binding of [ 125 I] Reg protein to cells expressing Reg-binding protein in the presence (100-fold excess) or absence ( ⁇ ) of unlabeled rat Reg protein.
- PCIneo indicates the result of a control transfected with an empty vector
- pCI ′ rEXTL3 indicates the result of a cell transfected with a rat Reg-binding protein expression vector. It is shown as the average soil standard error (sem) of four separate experiments.
- FIG. 7 is a diagram showing a functional analysis of a Reg receptor.
- A is a view showing BrdU incorporation by rat Reg protein into CH0 cells stably expressing a Reg receptor (Example 10). Two independent cell lines expressing Reg receptor (RegR- # 3 and RegR- # 22) were examined. The results are shown as the average standard error of the soil of eight separate experiments.
- B Competition binding curves of rat Reg (circle) and human REG (square) with rat Reg receptor. The results are shown as the mean soil standard error of four separate experiments.
- FIG. 8 is a diagram showing proliferation and apoptosis of Reg receptor-expressing /? Cells (Example 11). Three independent cell lines expressing the Reg receptor (# 1, # 6 and # 24) were examined. RIN stands for RINm5F control. The results are shown as the average standard error of the soil from 4 to 8 separate experiments.
- A Uptake of BrdU by rat Reg protein into RINm5F cells stably expressing Reg receptor.
- B Increase in cleavage of WST-1 by living cells by Reg protein.
- C Results of quantitative evaluation of apoptosis of RINm5F cells induced by Reg protein by TUNEL method.
- FIG. 9 shows the expression of Reg receptor mRNA (Example 12).
- the expression of Reg receptor mRNA was examined by RNase protection assay.
- the 309 base band is It corresponds to the size of protection by Reg receptor mMA.
- Lane 1 normal islets; lane 2, whole; lane 3, liver; lane 4, kidney; lane 5, heart; lane 6, spleen; lane 7, thymus; lane 8, testis; lane 9, adrenal gland; lane Lane 10; stomach; lane 11, jejunum; lane 12, ileum; lane 13, colon; lane 14, pituitary; lane 15, brain.
- FIG. 10 is a diagram showing that the degradation of WST-1 by viable cells in CH0 cells stably expressing the Reg receptor is increased by the Reg protein (Example 12). As in FIG. 7 (A), two independent cell lines were used. The results are shown as the mean soil standard error of eight separate experiments. BEST MODE FOR CARRYING OUT THE INVENTION
- the full length of the protein coding region of human REG I cDNA was determined by using the vector for expression of Pichia, pPIC3.5 (manufactured by Invitrogen). Was inserted into the SnaBI / Avrl site downstream of the yeast alcohol oxidase promoter by using phosphorylation to construct an expression vector.
- the full length of the protein coding region of rat Reg1 cDNA was inserted into the SnaBI / Notl site of PPIC3.5 using a linker.
- Expression vector DNA was purified by the CsC1 method, and introduced into a competent cell (Pichia GS115 strain) prepared using a Pichia Easy Comp Kit (manufactured by Invitrogen).
- Expression vector-introduced cells were selected for their ability to grow in a histidine-free medium. From the expression vector-introduced cells, a clone having the maximum human REG protein and rat Reg protein produced and secreted in the medium by the addition of methanol was selected.
- Pichia Pichia (Pichia pastoris) producing the above human REG protein or rat Reg protein was added to BMGY medium (1% yeast extract, 2% polypton, 100 mM potassium phosphate buffer (pH 6.0), 1.34% yeast nitro base). , 0.00004% biotin, 1% glycerol) at 28-30 ° C for 16-18 hours, followed by large-scale cultivation in BMGY medium until 0D ⁇ was 2-5.
- BMGY medium 1% yeast extract, 2% polypton, 100 mM potassium phosphate buffer (pH 6.0), 1.34% yeast nitro base).
- the yeast is collected by centrifugation, and BMMY medium (1% yeast extract, 2% polypeptone, 100 mM potassium phosphate buffer (pH 6.0), 1.34% Yeast Nitroge Base, 0.00004% biotin so that 0D 6M becomes 1 , 0.5% methanol) and cultured at 28-30 ° C for 3-4 days. During this time, methanol was added to a final concentration of 0.5% every 24 hours. The culture was collected by centrifugation, and acetic acid was added to adjust the pH to 3.5.
- BMMY medium 1% yeast extract, 2% polypeptone, 100 mM potassium phosphate buffer (pH 6.0), 1.34% Yeast Nitroge Base, 0.00004% biotin so that 0D 6M becomes 1 , 0.5% methanol
- the pH-adjusted culture solution is applied to STREAMLINE SP (Pharmacia) equilibrated with 50 mM sodium acetate (pH 3.5), washed with 50 ⁇ sodium acetate (pH 3.5), and then 50 mM sodium acetate (pH 3.5) /0.5 M Eluted with NaCl. It was confirmed by mass spectrometry that the produced protein was human REG protein or rat Reg protein, respectively.
- BrdU labeling solution (10 mM BrdU stock solution diluted to 100 ⁇ M with the medium) was added at 10 ⁇ l / ⁇ l (final concentration 10 ⁇ M BrdU).
- FixDenat (manufactured by Roche Diagnostics) was added at 200 ⁇ 1 / ⁇ .
- an anti-BrdU-POD antibody (diluted 1/100 of a stock solution (manufactured by Kuchig Diagnostics)) was added in a ratio of 100/1 / ⁇ .
- wash solution (10X wash solution (manufactured by Roche Diagnostics) diluted 1/10) washes 3 times at 200/1 / well. did.
- a substrate solution manufactured by Roche Diagnostics was added at 100 1 / ⁇ , and the mixture was incubated at room temperature until a sufficient color was obtained. The absorbance of each sample was measured at 370 nm using an ELISA reader (reference wavelength: about 492 nm).
- Rat Perangerhans Island Poly (A) + RNA was transformed into type III, and a Perangerhans island-expressed cDNA library was prepared using the ZAP II vector.
- Rat Reg protein prepared in Example 2 Bo 1 ton-Hunter reagent 125 1 labeled with, was selected and isolated phage clones that bind to Reg protein from the expression type cDNA Raipurari in West-Western method.
- the cDNA was recombined into a plasmid vector (pBluescript SK (-), manufactured by Stratagene) by an in vivo excision method using a helper phage from the positive phage clone.
- the nucleotide sequence of the cDNA was determined by the dideoxy method.
- the nucleotide sequence is shown in SEQ ID NO: 1, and the predicted amino acid sequence is shown in SEQ ID NO: 2.
- the protein deduced from the nucleotide sequence was considered to be a cell membrane protein having a transmembrane domain of one hydrophobic amino acid class.
- Example 5 The cDNA isolated in Example 5 was incorporated into a mammalian expression vector (pCI-neo) (Promega) having a cytomegalovirus promoter to construct a Reg-binding protein expression vector (pCI-167.1). Elect-mouth poration of this vector into COS-7 cells And transiently expressed. 48 hours after vector introduction, Reg binding activity was examined by the same protocol as in Example 4.
- the protein encoded by the isolated cMA is a molecule that binds to the Reg protein on mammalian cell membranes, and may be a receptor molecule responsible for the regenerative / proliferation activity of the Reg protein.
- a rat island cDNA library (5 ⁇ 10 6 clones) was screened by plaque hybridization to further isolate the cDNA encoding the Reg binding protein. As a result, eight positive clones were obtained. The eight clones largely overlapped each other, and the nucleotides in the overlapping region were completely identical.
- the sequence of the obtained cDNA encoding the rat Reg-binding protein is shown in SEQ ID NO: 3, and the amino acid sequence of the Reg-binding protein encoded by this cDNA is shown in SEQ ID NO: 4.
- this cDNA has a 2,760 bp open reading frame encoding a protein consisting of 919 amino acids.
- this protein Based on the amino acid sequence deduced from the cDNA, this protein has a long extracellular domain ( It was predicted to be a type II transmembrane protein having a transmembrane domain (residues 29 to 51) and a short intracellular region at the N-terminus.
- Example 7 An expression vector for the rat Reg-binding protein cDNA isolated in Example 7 was prepared and transiently expressed in COS-7 cells. Insert the rat Reg binding protein cDNA ligated with an oligonucleotide encoding this tag so that hemagglutinin (HA) nonapeptide-Y (YPYDVPDYA) is added to the N-terminus into the pCI-neo mammalian expression vector (Promega) This vector was then introduced into COS-7 cells by electroporation and expressed. After incubation for 48 hours, cells were harvested and described previously [S. Takasawa et al., J. Biol. Chem. 268, 26052 (1983); H. Okamoto et al., Meth. Enzymol. 280, 306].
- Rat Reg-binding protein (also referred to as rat EXTL3 / EXTR1) prepared in Example 8 An expression vector or a control vector is introduced into C0S-7 cells by electroporation. And expressed transiently. From these cells, CH0 cells stably expressing the Reg binding protein were isolated.
- RPMI1640 Roswel l Park Memorial Institute 1640
- 1 1 -labeled rat Reg protein 50ng / ml, 1.5 x l0 5 cpm / ml
- the cells were incubated with labeled rat Reg or human REG protein in RPMI 1640 containing 1% fetal calf serum on ice for 2 hours.
- RPMI 1640 After three washes with RPMI 1640, the cells were solubilized with 1 ml of lOOmM Tris-HCl (pH 7.6), ImM EDTA and l% Triton X-100.
- a homology search of the MA / protein database revealed that the rat Reg-binding protein cDNA (SEQ ID NO: 3) and the predicted amino acid sequence (SEQ ID NO: 4) contained multiple exostose (EXT) family members, especially human EXT.
- EXT exostose
- Gene 3 EXTL3
- EXTR1 ZEXT-related gene 1 (EXTR1)
- the cDNA is a rat homologue of human EXTL3 / EXTR1 (amino acid identity is greater than 97%).
- EXTL3 / EXTR1 The EXTL3 / EXTR1 gene was isolated as a member of the EXT family gene by homology screening, but its physiological function and pathophysiological significance are unknown.
- EXTL3 / EXTR1 has homology with EXT2 and EXT1 in the C-terminal region (262 amino acids at the C-terminal are 52% of EXT2 and 247 amino acids at the C-terminal are EXT1 and 40% of EXT1) (see Fig. 4). ), EXT family (W. Van Hui et al., Genomics 47, 230 (1998); T. Saito et al., Biochem. Biophys. Res. Co bandad un. 243, 61 (1998)). ing.
- the N-terminal region of EXTL3 / EXTR1 (residues 1 to 656) has no homology with any other member of the EXT family gene.
- the N-terminal region of EXTL3 / EXTR1 contains a transmembrane domain, while another member of the family does not contain this domain, and therefore It was not considered a protein.
- the 1.6 kbp cDNA originally isolated as a Reg binding protein in a screening of the rat islet cDNA expression library contained only the N-terminal region (amino acid residues 1-332). Therefore, it is reasonable to assume that the Reg binding domain is contained in the N-terminal region, and that members of the EXT family other than EXTL3 / EXTR1 have no binding ability to the Reg protein.
- rat Reg binding protein hereinafter also referred to as “rat Reg receptor” expression vector constructed in Example 8 was introduced into CH0 cells, and several cell lines overexpressing the receptor protein were established. We examined the uptake of 5'-bromo-2'-deoxyperidine (BrdU) into cells by protein stimulation.
- the HA-tagged rat Reg receptor expression vector was introduced into CH0 cells and RINm5F cells.
- Cells were cultured for 2 weeks in RPMI 1640 medium supplemented with 10% fetal calf serum (Bio Whittaker, Walerville, Maryland) and 250 ⁇ g / ml neomycin (Gibco) [S. Takasawa et al. , J. Biol. Chem. 273, 2497 (1998)].
- Stable transformants expressing high levels of the recombinant protein were screened and isolated by immunoblot analysis of HA.
- Stable transformants expressing the Reg receptor were cultured for 24 hours in RPMI 1640 medium supplemented with 1% fetal calf serum in the presence of various concentrations of rat Reg protein. Two hours before the end of the culture, BrdU (10 / M) was added to the medium, and BrdU incorporation was measured using a colorimetric cell proliferation ELISA kit (Boeringer).
- a human REG protein showing 70% amino acid identity to rat Reg protein (K. Terazono, et al., J. Biol. Chem. 263, 2111 (1988); K. Terazono, T. Watanabe, Y. Yonemura, in Molecular biology of the islets of Langerhans, H.
- Reg is recognized as a cell growth factor (H. Okamoto, J. Mol. Med. 77, 74 (1999); T. Watanabe et al., Proc. Natl. Acad. Sci. USA 91, 3589 ( 1994); DJ Gross et al., Endocrinology 139, 2369 (1998)).
- Addition of Reg protein to RINm5F cells a cell line derived from rat insulinoma, increases BrdU incorporation (1.5- to 2-fold) and increases the number of cells in a Reg protein concentration-dependent manner It has been found.
- the concentration of Reg protein that stimulates proliferation in RINm5F cells was consistent with that in primary rat islet cultures, suggesting that Reg protein acts through the same receptor in both cells.
- the expression vector constructed in Example 8 was introduced into RINm5F cells, several cell lines overexpressing the Reg receptor were established, and the effect of the Reg protein was examined using these cells.
- Rat regenerated knee islands were prepared as previously described (K. Terazono, et al., J. Am. Biol. Chem. 263, 2111 (1988); K. Terazono, T. Watanabe, Y. Yonemura, in Molecular biology of the islets of Langerhans, H. Okamoto, Ed. (Cambridge University Press, Cambridge, 1990), pp. 301-313; Y. Yonemura et al., Diabetes 33, 401 (1984)).
- RNA was isolated from various rat tissues and cell lines as previously described [T. Koguma et al., Biochem. Biophys. Acta 1223, 160 (1994); N. Noguchi et al., J. Biol Chem.
- Radzuto Reg receptor cDNA SEQ ID NO: 3 to Pstl / BgIII fragment of pBluescript SK (-) was subcloned into Pstl / BgUI site, after linearized with Hindlll T3 RNA polymerase and [shed - 32 P] CTP, And transcribed in vitro. The obtained 0.45 kb cRNA was used as a probe.
- RNase protection assay was performed using RPA III kit (Ambion) according to the instruction manual.
- Reg receptor mRNA was expressed in normal islets, regenerating islets and RINm5F cells. No increase in the expression of Reg receptors was observed in regenerating islets compared to normal islets, indicating that the amount of cells was increased. It was suggested that it might be regulated by protein expression.
- the Reg gene was first identified as a gene that is specifically expressed in regenerating ruto islands (K. Terazono, et al., J. Biol. Chem. 263, 2111 (1988); K. Terazono , T. Watanabe, Y. Yonemura, in Molecular biology of the islets of Langerhans, H. Okamoto, Ed.
- the present invention provides a protein (Reg receptor) that binds to Reg.
- Reg protein is a cell growth factor for five cells of the kidney, and is also known to exhibit cell growth activity in epithelial cells and the like.
- Reg-binding protein has the function of transmitting signals necessary for cell proliferation into cells by binding to Reg protein in kidney / cells. Renal ⁇ -cells are regenerated by binding of Reg protein and Reg-binding protein. It is thought that. Therefore, by analyzing the structure of the extracellular domain of the Reg-binding protein and searching for analogs of the ligand that binds to it, we have developed a therapeutic drug for diabetes that induces the proliferation of physiological tumor cells. Is possible.
- the Reg protein does not cause excessive proliferation of the cells in the kidney cells, it is considered that there is no possibility of expressing hypoglycemia due to excessive administration such as insulin administration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Rehabilitation Therapy (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002392514A CA2392514A1 (en) | 1999-06-10 | 2000-06-09 | Reg-binding protein |
KR1020017015854A KR20020033635A (ko) | 1999-06-10 | 2000-06-09 | Reg 결합단백질 |
AU51077/00A AU777139B2 (en) | 1999-06-10 | 2000-06-09 | Reg-binding protein |
EP00935616A EP1188828A4 (en) | 1999-06-10 | 2000-06-09 | REG-BINDING PROTEIN |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/164488 | 1999-06-10 | ||
JP16448899 | 1999-06-10 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10009178 A-371-Of-International | 2002-02-05 | ||
US10/866,259 Division US20040248184A1 (en) | 1999-06-10 | 2004-06-14 | Reg-binding protein |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000077192A1 true WO2000077192A1 (fr) | 2000-12-21 |
WO2000077192A9 WO2000077192A9 (fr) | 2002-01-17 |
Family
ID=15794125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/003764 WO2000077192A1 (fr) | 1999-06-10 | 2000-06-09 | Protéine se liant à reg |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1188828A4 (ja) |
KR (1) | KR20020033635A (ja) |
CN (1) | CN1361822A (ja) |
AU (1) | AU777139B2 (ja) |
CA (1) | CA2392514A1 (ja) |
WO (1) | WO2000077192A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1408333A3 (en) * | 2001-10-03 | 2006-10-25 | Pfizer Products Inc. | Diagnosis and treatment of Alzheimer's disease |
-
2000
- 2000-06-09 EP EP00935616A patent/EP1188828A4/en not_active Withdrawn
- 2000-06-09 CA CA002392514A patent/CA2392514A1/en not_active Abandoned
- 2000-06-09 WO PCT/JP2000/003764 patent/WO2000077192A1/ja active IP Right Grant
- 2000-06-09 KR KR1020017015854A patent/KR20020033635A/ko not_active Application Discontinuation
- 2000-06-09 CN CN00810465A patent/CN1361822A/zh active Pending
- 2000-06-09 AU AU51077/00A patent/AU777139B2/en not_active Ceased
Non-Patent Citations (4)
Title |
---|
See also references of EP1188828A4 * |
SEIICHI KOBAYASHI ET AL.: "Identification of a receptor for reg (regenerating gene) protein, a pancreatic beta-cell regeneration factor", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 15, 14 April 2000 (2000-04-14), pages 10723 - 10726, XP002931580 * |
TOSHIYUKI SAITO ET AL.: "Structure, chromosomal location and expression profile of EXTR1 and EXTR2, new members of the multiple exostoses gene family", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 243, no. 1, 1998, pages 61 - 66, XP002931578 * |
WIM VAN HUL ET AL.: "Identification of a third EXT-like gene (EXTL3) belonging to the EXT gene family", GENOMICS, vol. 47, no. 2, 1998, pages 230 - 237, XP002931579 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1408333A3 (en) * | 2001-10-03 | 2006-10-25 | Pfizer Products Inc. | Diagnosis and treatment of Alzheimer's disease |
Also Published As
Publication number | Publication date |
---|---|
CN1361822A (zh) | 2002-07-31 |
EP1188828A1 (en) | 2002-03-20 |
KR20020033635A (ko) | 2002-05-07 |
AU5107700A (en) | 2001-01-02 |
CA2392514A1 (en) | 2000-12-21 |
EP1188828A4 (en) | 2002-11-06 |
WO2000077192A9 (fr) | 2002-01-17 |
AU777139B2 (en) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5955306A (en) | Genes encoding proteins that interact with the tub protein | |
US20090136970A1 (en) | Nogo receptor homologues and their use | |
JPH06506598A (ja) | 副甲状腺ホルモンのレセプターとそれをコードしているdna | |
JPWO2003008446A1 (ja) | 後期糖化産物受容体のシグナル伝達に関連するポリペプチド | |
AU2010257887B2 (en) | SorCS1-like agent for use in the treatment of insulin resistance and diseases related thereto | |
US7972813B2 (en) | Tetrodotoxin-resistant sodium channel alpha subunit | |
WO1996018651A1 (en) | Human somatostatin-like receptor | |
JP4476491B2 (ja) | 新規膜貫通蛋白質をコードする遺伝子 | |
CA2477534A1 (en) | Cloning and characterization of slc26a6, slc26a1, and slc26a2 anion exchangers | |
ES2368072T3 (es) | Receptor de proteínas similares a tgr3. | |
WO1998046748A1 (en) | Therapeutic compositions and diagnostic assays for diseases involving trbp | |
WO2000077192A1 (fr) | Protéine se liant à reg | |
US7749758B2 (en) | Human and mammalian stem cell-derived neuron survival factors | |
WO2003057827A2 (en) | Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes | |
JP2001526030A (ja) | カドヘリン様ポリペプチド、それに関連する方法および組成物 | |
WO1999041376A9 (en) | Retinoblastoma protein complexes and retinoblastoma interacting proteins | |
US20040248184A1 (en) | Reg-binding protein | |
JP2002171977A (ja) | 新規なヒトsh2蛋白質 | |
JP2006166703A (ja) | 軟骨分化制御遺伝子 | |
JP2000125862A (ja) | 新規な哺乳類のタンパク質及びそれをコードするポリヌクレオチド | |
US20080200408A1 (en) | Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit | |
JP2003024075A (ja) | 新規チロシンキナーゼ遺伝子及びそれにコードされるタンパク質 | |
JP2006166704A (ja) | 軟骨分化抑制遺伝子 | |
WO2001030840A1 (fr) | Nouveau polypeptide, une proteine 57 a doigt de zinc, et polynucleotide codant pour ce polypeptide | |
WO2001029076A1 (fr) | Nouveau polypeptide, une proteine-22 humaine p24, et polynucleotide codant pour ce polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2001 503637 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017015854 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2392514 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 51077/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000935616 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PUBLISHED STATEMENT CONCERNING NON-PREJUDICIAL DISCLOSURE OR EXCEPTION TO LACK OF NOVELTY, REPLACED BY CORRECT STATEMENT |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008104654 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10009178 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000935616 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 51077/00 Country of ref document: AU |